COVID-19 in adult acute myeloid leukemia patients : a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Marchesi, Francesco (IRCCS Regina Elena National Cancer Institute)
Salmanton-García, Jon (University of Cologne)
Emarah, Ziad (Mansoura University)
Piukovics, Klára (Medicine University of Szeged)
Nucci, Marcio (Federal University of Rio de Janeiro)
López-García, Alberto (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Rácil, Zdenék (Institute of Hematology and Blood Transfusion)
Farina, Francesca (IRCCS San Raffaele Scientific Institute (Milà, Itàlia))
Popova, Marina (Pavlov University)
Zompi, Sofia (AOU Citta' della Salute e della Scienza)
Audisio, Ernesta (AOU Citta' della Salute e della Scienza)
Ledoux, Marie-Pierre (Institut de Cancérologie Strasbourg Europe)
Verga, Luisa (Università Milano-Bicocca)
Weinbergerová, Barbora (University Hospital Brno (República Txeca))
Szotkovski, Tomas (University Hospital Olomouc (Olomouc, República Txeca))
Da Silva, Maria Gomes (Portuguese Institute of Oncology)
Fracchiolla, Nicola (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
De Jonge, Nick (Amsterdam UMC)
Collins, Graham (Oxford University Hospitals)
Marchetti, Monia (Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e Cesare Arrigo")
Magliano, Gabriele (ASST Grande Ospedale Metropolitano Niguarda)
Garcia-Vidal, Carolina (Universitat de Barcelona)
Biernat, Monika M. (Wroclaw Medical University)
Van Doesum, Jaap (University Medical Center Groningen)
Machado, Marina (Hospital General Universitario Gregorio Marañón)
Demirkan, Fatih (Dokuz Eylul University)
Al-Khabori, Murtadha (Sultan Qaboos University Hospital)
Žák, Pavel (University Hospital Hradec Kralove (República Txeca))
Víšek, Benjamín (University Hospital Hradec Kralove (República Txeca))
Stoma, Igor (Gomel State Medical University, Gomel)
Méndez, Gustavo-Adolfo (Hospital Escuela de Agudos Dr. Ramón Madariaga)
Maertens, Johan (KU Leuven)
Khanna, Nina (University Hospital Basel (Basilea, Suïssa))
Espigado, Ildefonso (Universidad de Sevilla)
Dragonetti, Giulia (Fondazione Policlinico Universitario Agostino Gemelli)
Fianchi, Luana (Fondazione Policlinico Universitario Agostino Gemelli)
Del Principe, Maria Ilaria (Tor Vergata University of Rome)
Cabirta, Alba (Vall d'Hebron Institut d'Oncologia)
Ormazabal-Vélez, Irati (Complejo Hospitalario de Navarra)
Jakšić, Ozren (University Hospital Dubrava)
Buquicchio, Caterina (Ematologia con Trapianto (Itàlia))
Bonuomo, Valentina (University of Verona)
Batinié, Josip (University Hospital Centre Zagreb)
Omrani, Ali S. (Hamad Medical Corporation)
Lamure, Sylvain (Universite de Montpellier)
Finizio, Olimpia (Università Cattolica del Sacro Cuore)
Fernández, Noemí (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Falces-Romero, Iker (Hospital Universitario La Paz (Madrid))
Blennow, Ola (Karolinska University Hospital and Karolinska Institutet (Suècia))
Bergantim, Rui (Centro Hospitalar e Universitário São João (Portugal))
Ali, Natasha (Aga Khan University Hospital)
Win, Sein (Yangon General Hospital)
Van Praet, Jens (AZ Sint-Jan Brugge-Oostende)
Tisi, Maria Chiara (Ospedale San Bortolo)
Shirinova, Ayten (Azerbaijan Scientific Research Hematology and Transfusiology Institute)
Schönlein, Martin (University Medical Center Hamburg-Eppendorf)
Prattes, Juergen (Medical University of Graz)
Piedimonte, Monica (AOU Sant'Andrea)
Petzer, Verena (Medical University of Innsbruck)
Navrátil, Milan (University Hospital of Ostrava)
Kulasekararaj, Austin (King's College Hospital NHS Foundation Trust)
Jindra, Pavel (University Hospital Pilsen)
Sramek, Jirí (University Hospital Pilsen)
Glenthøj, Andreas (Copenhagen University Hospital)
Fazzi, Rita (Azienda Ospedaliera Università Pisana)
De Ramón-Sánchez, Cristina (Instituto de Investigación Biomédica de Salamanca)
Cattaneo, Chiara (ASST-Spedali Civili)
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid))
Bahr, Nathan C. (University of Kansas Medical Center)
El-Ashwah, Shaimaa (Mansoura University)
Cordoba, Raul (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Hanakova, Michaela (Institute of Hematology and Blood Transfusion)
Zambrotta, Giovanni (Azienda Ospedaliera San Gerardo)
Zambrotta, Giovanni (Università Milano-Bicocca)
Sciumè, Mariarita (IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Booth, Stephen (Oxford University Hospitals)
Rodrigues, Raquel Nunes (Portuguese Institute of Oncology)
Sacchi, Maria Vittoria (Azienda Ospedaliera Nazionale "SS. Antonio e Biagio e Cesare Arrigo")
García-Poutón, Nicole (Universitat de Barcelona)
Martín-González, Juan-Alberto (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Khostelidi, Sofya (North-Western State Medical University named after Iliá Ilich Méchnikov)
Gräfe, Stefanie (University of Cologne)
Rahimli, Laman (University of Cologne)
Ammatuna, Emanuele (University Medical Center Groningen)
Busca, Alessandro (AOU Citta' della Salute e della Scienza)
Corradini, Paolo (University of Milan)
Hoenigl, Martin (Medical University of Graz)
Klimko, Nikolai (North-Western State Medical University named after Iliá Ilich Méchnikov)
Koehler, Philipp (University of Cologne)
Pagliuca, Antonio (King's College Hospital NHS Foundation Trust)
Passamonti, Francesco (University of Insubria and ASST Sette Laghi)
Cornely, Oliver A. (University of Cologne)
Pagano, Livio (Università Cattolica del Sacro Cuore)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41. 2% and critical in 21. 1% of cases. The chemotherapeutic schedule was modified in 174 patients (44. 8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46. 4%) had died; death was attributed to COVID-19 (43. 3%), AML (26. 1%) or to a combination of both (26. 7%), whereas in 3. 9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P <0. 001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39. 8% vs. 60% vs. 61. 9%, respectively; P =0. 006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Haematologica, Vol. 108 (may 2022) , p. 22-33, ISSN 1592-8721

DOI: 10.3324/haematol.2022.280847
PMID: 35545919

12 p, 770.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats